- Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036.doi:https://doi.org/10.1136/bmj.m1036.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;30079–5. doi:https://doi.org/10.1016/S2213-2600(20). Epub ahead of print 24 February 2020.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA. 2020; Epub ahead of print 7 February 2020. 323(11):https://doi.org/10.1001/jama.2020.1585.
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271.e8–280.e8.doi:https://doi.org/10.1016/j.cell.2020.02.052.
- Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, Schmitto JD, Heineke J, Emrich F, Arsalan M, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;April. 15. Epub ahead of print. 41(19): https://doi.org/10.1093/eurheartj/ehaa311.
- Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM.Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(1):45–51.doi:https://doi.org/10.1042/BJ20040634.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–62. doi:https://doi.org/10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
- Soler MJ, Barrios C, Oliva R, Batlle D.Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008;10(5):410–14.doi:https://doi.org/10.1007/s11906-008-0076-0.
- Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE.Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10.doi:https://doi.org/10.1161/CIRCULATIONAHA.104.510461.
- Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi:https://doi.org/10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11
- Sommerstein R, Gräni C. Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ. 2020;368:m810.
- Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020 March;27(3):18. doi:https://doi.org/10.1093/jtm/taaa041.
- Vaduganathan M, Vardeny O, Michel T, Jjv M, Pfeffer MA, Solomon SD.Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–59.doi:https://doi.org/10.1056/NEJMsr2005760.
- National Health Commission of the People’s Republic of China website. Diagnosis and treatment of novel coronavirus infection (trial version 6). https://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. Published 18 Feb 2020.
- World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Interim guidance. 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases–20200117
- Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 INFECTION) GUIDE. https://hsgm.saglik.gov.tr/depo/birimler/goc_sagligi/covid19/rehber/COVID-19_Rehberi20200414_eng_v4_002_14.05.2020.pdf
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. 2020. https://www.who.int/publications-detail/clinicalmanagement-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
- Avdeev SN, Yaroshetskiy AI, Tsareva NA, Merzhoeva ZM, Trushenko NV, Nekludova GV, Chikina SY. Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. Am J Emerg Med. 2021 Jan;39:154–57. Epub 2020 Oct 1. doi:https://doi.org/10.1016/j.ajem.2020.09.075.
- Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J, Faucher E, Nyunga M, Girault C, Perez P, Guitton C, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015 Oct 27;314(16):1711–19. doi:https://doi.org/10.1001/jama.2015.12402.
- Price S, Singh S, Ledot S, Bianchi P, Hind M, Tavazzi G, Vranckx P. Respiratory management in severe acute respiratory syndrome coronavirus 2 infection. Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):229–38. doi:https://doi.org/10.1177/2048872620924613. Epub 2020 May 7.
- Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020 Apr;23:e201624. Online ahead of print. doi:https://doi.org/10.1001/jamacardio.2020.1624.
- Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, Song Q, Jia Q, Wang J, Jin X. Clinical characteristics of 82 death cases with COVID-19. PLoS One. 2020;15(7):e0235458. doi:https://doi.org/10.1371/journal.pone. 0235458.
- Shi Q, Zhao K, Yu J, Feng J, Zhao K, Zhang X, Chen X, Hu P, Hong Y, Li M, et al. Clinical characteristics of 101 non-survivors hospitalized with COVID-19 - a single center, retrospective study. medRxiv. 2020; published online. May. 20. https://doi.org/10.1101/2020.03.04.20031039.
- Varagic J, Ahmad S, Nagata S, Ferrario CM.ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16(3):420.doi:https://doi.org/10.1007/s11906-014-0420-5.
- Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–79.doi:https://doi.org/10.1038/nm1267.
- Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, LeongPoi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–16.doi:https://doi.org/10.1038/nature03712.
- Kuba K, Imai Y, Penninger JM.Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006;6(3):271–76.doi:https://doi.org/10.1016/j.coph.2006.03.001.
- Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–74.doi:https://doi.org/10.1007/s11427-020-1643-8.
- Serfozo P, Wysocki J, Gulua G, Schulze A, Ye M, Liu P, Jin J, Bader M, Myöhänen T, García-Horsman JA, et al. Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension. 2020;75(1):173–82. doi:https://doi.org/10.1161/HYPERTENSIONAHA.119.14071.
- Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC Jr, Llorens-Cortes C, Ehlers MR, Sturrock ED, Barker EL. 2019. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 71(4):539–70. doi:https://doi.org/10.1124/pr.118.017129
- Danser AHJ, Epstein M, Renin-Angiotensin System BD. Blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020 Jun;75(6):1382–85. doi:https://doi.org/10.1161/HYPERTENSIONAHA.120.15082.
- Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. Apr 27 2020:32341442. doi:https://doi.org/10.1038/s41440-020-0455-8. PMID.
- Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, et al. Renin angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–60.doi:https://doi.org/10.1080/22221751.2020.1746200.
- Li Y, Zeng Z, Li Y, Huang W, Zhou M, Zhang X, Jiang W.Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation. Shock. 2015;43(4):395–404.doi:https://doi.org/10.1097/SHK.0000000000000302.
- Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al. Association of inpatient use of enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID‐19. Circ Res. 2020;126:1671–81.
- Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, Xiao X, Qin Q. The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: a systematic review and meta‐analysis. J Med Virol. 2020;26625. doi:https://doi.org/10.1002/jmv.26625.
- Pirola CJ, Sookoian S. Estimation of renin–angiotensin–aldosterone–system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis. J Infect. 2020 Aug;81(2):276–81. doi:https://doi.org/10.1016/j.jinf.2020.05.052. Epub 2020 May 28.
- Liu H, Zhao J.An experimental study of therapeutic effect of ACEI on chemicalinduced ARDS in rats. Zhonghua Yu Fang Yi Xue Za Zhi. 2002;36(2):93–96.
- Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, Van Woensel JB, Van Der Loos CM, Van Goor H, Kamilic J, Florquin S, Bos AP.Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618–27.doi:https://doi.org/10.1002/path.2987.
The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients
View further author information
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.